{"id":516211,"date":"2021-07-22T07:04:18","date_gmt":"2021-07-22T11:04:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/"},"modified":"2021-07-22T07:04:18","modified_gmt":"2021-07-22T11:04:18","slug":"plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/","title":{"rendered":"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial"},"content":{"rendered":"
\n

\n Recurrent Glioblastoma Trial Update Planned for Q4 2021<\/em>
\n \n <\/p>\n

AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV<\/a>) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the first patient in the eighth cohort of the Phase 1 dose escalation ReSPECT\u2122-GBM clinical trial for recurrent glioblastoma (rGBM) has been successfully treated. The present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort.<\/p>\n

\u201cThe ReSPECT\u2122-GBM Phase 1 clinical trial is progressing on schedule and with an acceptable safety profile,\u201d said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. \u201cWe plan to provide an update on the trial in the fourth quarter of 2021.\u201d<\/p>\n

Twenty-two patients across eight dosing cohorts have been treated in the ReSPECT\u2122 trial to date. Thus far, no treatment emergent dose-limiting toxicities have been observed, despite absorbed radiation doses to the tumor of up to 740 Gray.<\/p>\n

\n About Plus Therapeutics, Inc.<\/strong>\n <\/p>\n

Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company\u2019s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and\/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at\u00a0PlusTherapeutics.com<\/u><\/a> and ReSPECT-Trials.com<\/u><\/a>.<\/p>\n

\n Cautionary Statement Regarding Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains statements that may be deemed \u201cforward-looking statements\u201d within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as \u201cwill,\u201d \u201cbelieve,\u201d \u201cplan,\u201d \u201ccan,\u201d \u201cenable,\u201d \u201cdesign,\u201d \u201cintend,\u201d \u201cpotential,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cprospect,\u201d \u201ctarget,\u201d \u201cfocus,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cshould,\u201d and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the Company\u2019s anticipated expenditures, including research and development, sales and marketing, and general and administrative expenses; anticipated benefits of strategic collaborations and license agreements, intellectual property, FDA approval process and government regulation; the Company\u2019s ability to benefit from the NIH\/NCI award for continued clinical development of 186<\/sup>RNL for recurrent glioblastoma; the ability of 186<\/sup>RNL to safely and effectively deliver radiation directly to the tumor at high doses; the Company\u2019s ability to expand clinical testing of 186<\/sup>RNL to additional sites; the potential size of the market for the Company\u2019s product candidates; the Company\u2019s research and development efforts; the Company\u2019s IP strategy; competition; future development and\/or expansion of its product candidates and therapies in its markets; the Company\u2019s ability to generate product or development revenue and the sources of such revenue; the amounts that the Company may be obligated to pay under license agreements; the Company\u2019s ability to effectively manage its gross profit margins; its ability to obtain and maintain regulatory approvals; expectations as to the Company\u2019s future performance; the Company\u2019s need for additional financing and the availability thereof; its ability to fully access its equity line with Lincoln Park; any changes to its interest expenses; the Company\u2019s ability to continue as a going concern; its ability to remain listed on the Nasdaq Capital Market; the Company\u2019s ability to repay or refinance some or all of its outstanding indebtedness and its ability to raise capital in the future; expectations as to the impact of recently issued or adopted accounting standards; the Company\u2019s expectations as to the impact of the COVID-19 pandemic on its business and operating results; the Company\u2019s beliefs as to the impact of any liability that may arise as a result of any legal proceedings; and the potential enhancement of the Company\u2019s cash position through development, marketing, and licensing arrangements.<\/p>\n

The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company\u2019s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company\u2019s product candidates and therapies, the results of the Company\u2019s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company\u2019s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company\u2019s partnering\/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading \u201cRisk Factors\u201d in the Company\u2019s Securities and Exchange Commission filings, including in the Company\u2019s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.<\/p>\n

\n Investor Contact<\/strong>
\n
Peter Vozzo
Westwicke\/ICR
(443) 377-4767
Peter.Vozzo@westwicke.com<\/p>\n

\n Media Contact<\/strong>
\n
Terri Clevenger
Westwicke\/ICR
(203) 856-4326
Terri.Clevenger@westwicke.com<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Recurrent Glioblastoma Trial Update Planned for Q4 2021 AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the first patient in the eighth cohort of the Phase 1 dose escalation ReSPECT\u2122-GBM clinical trial for recurrent glioblastoma (rGBM) has been successfully treated. The present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort. \u201cThe ReSPECT\u2122-GBM Phase 1 clinical trial is progressing on schedule and with an acceptable safety profile,\u201d said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. \u201cWe plan to provide an update on the trial in … <\/p>\n

Continue reading “Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-516211","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPlus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Recurrent Glioblastoma Trial Update Planned for Q4 2021 AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the first patient in the eighth cohort of the Phase 1 dose escalation ReSPECT\u2122-GBM clinical trial for recurrent glioblastoma (rGBM) has been successfully treated. The present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort. \u201cThe ReSPECT\u2122-GBM Phase 1 clinical trial is progressing on schedule and with an acceptable safety profile,\u201d said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. \u201cWe plan to provide an update on the trial in … Continue reading "Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-22T11:04:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial\",\"datePublished\":\"2021-07-22T11:04:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/\"},\"wordCount\":976,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/\",\"name\":\"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=\",\"datePublished\":\"2021-07-22T11:04:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/","og_locale":"en_US","og_type":"article","og_title":"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial - Market Newsdesk","og_description":"Recurrent Glioblastoma Trial Update Planned for Q4 2021 AUSTIN, Texas, July 22, 2021 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq:\u00a0PSTV) (the \u201cCompany\u201d), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the first patient in the eighth cohort of the Phase 1 dose escalation ReSPECT\u2122-GBM clinical trial for recurrent glioblastoma (rGBM) has been successfully treated. The present cohort implements a 40% increase in volume (12.3 milliliters) and total radioactivity (31.2 millicuries) from the previous cohort. \u201cThe ReSPECT\u2122-GBM Phase 1 clinical trial is progressing on schedule and with an acceptable safety profile,\u201d said Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics. \u201cWe plan to provide an update on the trial in … Continue reading \"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-22T11:04:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial","datePublished":"2021-07-22T11:04:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/"},"wordCount":976,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/","name":"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=","datePublished":"2021-07-22T11:04:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI4NDc0MyM0MzA5MTE2IzIwMDQ4MDU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/plus-successfully-treats-first-patient-in-latest-dosing-cohort-in-respect-gbm-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Plus Successfully Treats First Patient in Latest Dosing Cohort in ReSPECT\u2122-GBM Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516211","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=516211"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/516211\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=516211"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=516211"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=516211"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}